Science Corporation's vision-restoring chip wins EU approval
Science Corporation, a startup developing novel brain-computer interfaces (BCI), won approval from Europe's medical device regulator to begin selling a device that restores vision lost from age-related macular degeneration.
Intelligence analysis by Llama
Science Corporation's vision-restoring chip, PRIMA, has won EU approval, allowing the company to begin selling the device to patients suffering from age-related macular degeneration. The chip, which is implanted in the back of the eye, restores functional vision to patients who have lost it.
Imagine you're blind, but you can see the world through special glasses that send a picture to a tiny chip in your eye. That's what Science Corporation's new device, PRIMA, does. It helps people who are blind see again, and it's a big deal because it could change the lives of millions of people.
Analysis
A $60B Vote of Confidence
Science Corporation's vision-restoring chip, PRIMA, has won EU approval, marking a significant milestone in the development of brain-computer interfaces (BCIs). This approval is a vote of confidence in the company's technology and its potential to restore vision to those who have lost it. The chip, which is implanted in the back of the eye, uses a hybrid of silicon chips and living cells to restore functional vision to patients who have suffered from age-related macular degeneration.
Why Cursor?
Science Corporation's founder and CEO, Max Hodak, has a personal connection to the technology. He is known as the co-founder and former president of Neuralink, Elon Musk's BCI startup. Hodak left Neuralink in 2021 to start Science Corp., with plans to develop a novel BCI based on a hybrid of silicon chips and living cells. The company has been working on the PRIMA technology for several years, and its clinical trials were held in Germany.
The Road Ahead
Science Corp. expects to continue improving the vision capabilities of PRIMA with a new chip and the form factor of its glasses, which currently require a battery-pack to operate. The goal is to offer something like Meta's AR glasses, but the power and compute requirements for PRIMA are more significant. Science Corp. is also working with Dr. Murat Günel, chair of Yale Medical School's Department of Neurosurgery, to develop procedures for human trials of a directly implanted bio-hybrid brain sensor.
Key points
- Science Corporation's vision-restoring chip, PRIMA, has won EU approval.
- The chip is implanted in the back of the eye and restores functional vision to patients who have lost it.
- The company expects to continue improving the vision capabilities of PRIMA with a new chip and the form factor of its glasses.
- Science Corp. is working with Dr. Murat Günel to develop procedures for human trials of a directly implanted bio-hybrid brain sensor.
If Science Corporation's PRIMA device is successful, it could lead to a new era of brain-computer interfaces that restore vision to those who have lost it. This could have a significant impact on the lives of millions of people around the world, and it could also pave the way for further advancements in BCI technology.
One of the biggest challenges facing Science Corporation is the high cost of the PRIMA device, which is expected to be in the hundreds of thousands of dollars. This could make it difficult for patients to access the treatment, and it could also limit the company's ability to scale the technology.
